Stock Trading Canary
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 9Developing evidence | 52.9% (9/17) | 66.7% (6/9) | +13.7% | +15.1% | -17.9% |
| 20D | 8Developing evidence | 50.0% (8/16) | 75.0% (6/8) | +43.4% | +37.6% | -28.3% |
| 60D | 8Developing evidence | 53.3% (8/15) | 87.5% (7/8) | +261.9% | +204.9% | -16.6% |
| 120D | 8Developing evidence | 57.1% (8/14) | 87.5% (7/8) | +166.8% | +147.0% | -12.8% |
COMPANY RESEARCH
Scholar Rock Holding Corp
SRRK · United States · Healthcare
Insider Signal
Snapshot: 05 Nov 2026 · 180-day research window
- Insider Signal
- 67.8 / 100 Research score, not a buy recommendation
- Reported buyers
- 1 180-day scoring window
- Net purchases
- 11.08m USD 180 days · purchases less sales
- Latest disclosure
- 2026-10-27 Publication date
What stands out
- AKKARAJU SRINIVAS accounts for 100% of comparable reported purchase value; buyer breadth and value are different measures.
Price vs insider buying
SRRK · USD● Purchase × Sale ◇ Public disclosure ▥ 15-day cluster ·
Circles and crosses mark trade dates; diamonds below the axis mark later public disclosures. The trade became public on its disclosure date. Prices are nearest-session closes, not insider execution prices. Marker sizes are not compared when values or currencies differ.
BULL VS BEAR
Two readings of this buying
The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.
Where the evidence comes from
The two kinds of evidence disagree: the purchases themselves carry bull lines (large purchases, buyer's past purchases beat the benchmark, bought in the last two weeks), while short sellers argue against (high short interest). No data is held for: company results, company actions.
- The insider purchases themselvesBulllarge purchases, buyer's past purchases beat the benchmark, bought in the last two weeks Bearone buyer only3 checked, under the threshold · 2 missing
- Share price and trading2 checked, under the threshold
- Short sellersBearhigh short interest1 checked, under the threshold
- Company results2 missing
- Company actionsno data held
Bull case · the buying is informative
- Insiders committed a net $11.1M of their own money in 180 days.
- The 8 earlier purchases by AKKARAJU SRINIVAS beat S&P 500 ETF (SPY adjusted close) by a median 262% over the following 60 trading days.
- The latest purchase is 10 days old (2026-10-26). The buying is current, not left over from an earlier quarter.
Bear case · discount it
- Only one insider bought. A single purchase can reflect that person's own finances rather than a view on the company.
- Short sellersFINRA short interest on 2026-10-15 was 22,175,999 shares, 12.7 days of average trading volume and 18% of the 121,785,282 shares outstanding, down 2.4% from the previous report: other investors hold a sizeable position the opposite way.
Evidence still missing
- The company's market value is not captured, so the purchases cannot be stated as a share of the business or of its trading volume.
- No earnings, margin or cash-flow figures are captured for this company. The latest annual and interim reports are where to check whether the business is improving or deteriorating.
- The 10b5-1 box of these Form 4 filings has not been read, so whether the purchases followed a pre-arranged plan is not known.
- Form 4 states the shares held after each trade. This site reads that from the SEC's quarterly data, which is published after a quarter ends, so it does not have it yet for these filings. Whether a purchase added 1% to a personal stake or doubled it is in the filing, not on this page.
Checked and under the threshold: 6
- Either1 insider bought in the last 180 days and 0 in the 180 days before. Bull when the number at least doubles and rises by two; bear when at least two bought before and no more buy now.
- BearInsiders sold $923k in the same 180 days, 7.7% of the amount bought. Counted for the bear side from 25%.
- BearThe share price changed −2.0% over six months (three months −14%, one month +7.8%) and stands 26% below its 52-week high. Counted for the bear side from a fall of 20%.
- BearOver three months the share price changed −14% and the median of 220 Healthcare companies changed −18%: ahead by 4 points. Counted for the bear side from 20 points behind.
- BearOver the last 5 trading days to 2026-11-05, 67% of this stock's off-exchange volume was sold short; over the 60 days before, 67%. The market's median is 47%. This is trading volume, not a position: a market maker who sells short and covers the same day is counted, so about half of all volume is short on an ordinary day. It is shown for comparison and counts for neither side.
- BearNo insider filing in the last 180 days opened a hedge on this stock.
Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.
Who is trading?
Named filings in 180 days. Purchase values are summed only when complete and in one currency.
| Insider | Transaction activity | Purchase value | Latest trade | Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AKKARAJU SRINIVASBoard member | 6 buy · 0 sell | 12.00m USD | 2026-10-26 | View transactions · 7
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Brudnick RichardBoard member | 0 buy · 0 sell | No purchases | 2026-06-04 | View transactions · 1
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Burow KristinaBoard member | 0 buy · 2 sell | No purchases | 2026-07-01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| FLIER JEFFREY S.Board member | 0 buy · 3 sell | No purchases | 2026-07-01 | View transactions · 4
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Gilman MichaelBoard member | 0 buy · 3 sell | No purchases | 2026-07-01 | View transactions · 4
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hallal DavidCEO / chair | 0 buy · 0 sell | No purchases | 2026-09-21 | View transactions · 1
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Peng KatieBoard member | 0 buy · 3 sell | No purchases | 2026-07-01 | View transactions · 4
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reed JoshuaBoard member | 0 buy · 2 sell | No purchases | 2026-07-01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Woods KeithExecutive | 0 buy · 0 sell | No purchases | 2026-09-24 | View transactions · 1
|
INSIDER SIGNAL
Score breakdown：67.8 / 100
1 insiders · 2 purchase events · $11.08m net purchases
US #180 · United States #180
WHY THIS SIGNAL?
Score anatomy
Each bar is that part's points in the score; the five parts add up to the score.
Number of buyers+7.0 / 35
How many different insiders bought within 15 days
Amount bought+23.1 / 25
The value bought, net of any insider sales
Buyers' roles+20.0 / 20
Lower in the company scores higher: in the backtest, purchases by the most senior insiders did worse
How recent+8.5 / 10
How long ago the latest purchase took place
Buying against selling+9.2 / 10
Lower when insiders also sold
What is holding the score back?
- ⚠ Few buyers · fewer than 4 different insiders
- ✓ Buyers' roles add a lot · the buyers are below the top of the company
- ✓ Recent buying · latest purchase 2026-10-26
Buyers' roles follow the US order of roles: CEOs, chairs and 10% owners score lowest.
Buying concentration
100%
Largest buyer：AKKARAJU SRINIVAS · 12.00m USD
Purchases counted, before sales：12.00m USD
The amount at the top of the page is purchases minus sales; this one counts purchases only, in the filing currency, so the two can differ. The score counts how many people bought; this shows separately who bought the most.
This is a ranking under the current US screening rules—not a probability of gain, return forecast, or buy recommendation.
Key purchase quotes (filing currency)
| Filer | Price per unit | Trade date |
|---|---|---|
| AKKARAJU SRINIVAS | 41.59 USD | Oct 26, 2026 |
| AKKARAJU SRINIVAS | 41.31–41.82 USD | Oct 23, 2026 |
Model details
Cluster breakdown (does not change the score)
- 15-day buyer breadth (count)
- 1 distinct reported filers
- Peak time window
- 2026-10-23 to 2026-10-26
- Current breadth input
- 0.200 (capped at 4+ buyers)
- Buyer independence
- Not yet measured; related-party fields are not cross-market comparable
What the filings show
- 🟢 Latest purchase counted
AKKARAJU SRINIVAS · 6.11m USD · Price 41.59 USD · Oct 26, 2026 - 🟢 Purchase by a manager or director
AKKARAJU SRINIVAS · 5.89m USD · Price 41.31–41.82 USD · Oct 23, 2026 - 🔴 22 other line(s) are not counted, as they are not purchases the insider chose to make; 9 have a price of zero
Filing and data quality
These checks are auditable context; they do not change the rank or score.
- Identity match
- REVIEW
- Ticker / ISIN
- Ticker or ISIN missing
- Filing source links
- 79 / 79
- Median disclosure lag
- 2 days
- Latest disclosure age
- 9 days at snapshot
- Corrections / revisions
- 0
- Score-factor detail
- Saved
Insider timeline
One insider bought, 2 times, the latest (26 Oct). The share closed at 41.71 that day and at 45.50 most recently (+9.1%).
Tap an item for what it means.
●A purchase: the bigger the dot, the more was bought
Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount.
×A sale
A cross is one insider's sales on one day. People sell to pay tax, to cash in share awards or to hold less of one company, so a sale says less than a purchase does. When someone bought and sold on the same day, the cross sits beside the dot. The totals are under “Purchases against sales” below.
Blue line: this share's price, −5.9% over these six months
The closing price of each day, from 48.35 on 2026-05-11 to 45.50 on 2026-11-05. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.
Dashed line: the typical stock on the same exchange, −9.7%
Taken from the 1610 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share −5.9%, the typical one −9.7%, 3.8 points ahead. It is not an index and not a comparison within one industry.
▂Grey bars: companies across United States disclosing purchases each week
A taller bar is a week in which more companies disclosed insider purchases.
This company: insiders buying per month, last 12 months
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
1Oct
Nov
Darker bars are inside the 180-day window above.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since |
|---|---|---|---|---|---|---|
| Burow Kristina | Board member | — | 1 | — | — | — |
| FLIER JEFFREY S. | Board member | — | 1 | — | — | — |
| Gilman Michael | Board member | — | 1 | — | — | — |
| Peng Katie | Board member | — | 1 | — | — | — |
| Reed Joshua | Board member | — | 1 | — | — | — |
| AKKARAJU SRINIVAS | Board member | 2 | — | 12.0M USD | 2026-10-23 | +9.7% |
Purchases against sales
Purchases93%12.0M USD · 6 line(s) · 1 insider(s)
Sales7%923.1k USD · 13 line(s) · 5 insider(s)
Shares of the reported value of insider transactions in the 180-day window. Sales include disposals for tax, at option exercise or under a pre-set plan, which say little about an insider's view. The split describes what was disclosed; it is not a signal.
Insiders' buying price vs the latest close
Insiders paid 41.45 USD a share on average (6 purchase lines, 1 buyer, 2026-10-23 – 2026-10-26). The close on 2026-11-05 was 9.8% above that price.
The latest purchase (2026-10-26) was at 41.59 USD; the close was 9.4% above that price.
Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored.
Buying size vs market trading
Complete price and volume history is not yet available.
Market-data coverage: 0 verified sessions · Latest session: — · Ratio status: Unavailable
Traded value is estimated as close × shares traded, in major currency units. Includes disclosed qualifying purchases; disclosures may lag. Contractual or planned acquisitions are not necessarily discretionary. Ratios describe relative trading size, not market participation or score contributions.
Sector context
- Buying breadth
- 4.1% (42 / 1,020 issuers)
- Sector rank
- #7 / 13
This is sector-level research context. It does not affect the Insider Signal or ranking.
Insider profile outcomes
Historical performance following insider filings. The company role is translated below each name while preserving the original title.
- Excess return = stock return − S&P 500 ETF (SPY adjusted close) return over the same period.
- Hit rate = completed events with positive excess return ÷ total completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
- Small-sample rule: n<5 is shown for transparency and is not scored.
Events are disclosure-level observations; related disclosures published on the same date may share a return path and may not be statistically independent. This research enrichment does not affect the insider score or ranking.
Signal outcomes
Calculated from immutable US ranking snapshots; excess return is stock return minus SPY return. Newly saved snapshots remain pending until each forward horizon matures. This never affects the US score.
| Horizon | Status | Result |
|---|---|---|
| 5D | Awaiting maturity | — |
| 20D | Awaiting maturity | — |
| 60D | Awaiting maturity | — |
| 120D | Awaiting maturity | — |
Market context
PRICE PERFORMANCE
VOLATILITY & LIQUIDITY
- Volatility
- 63.5%
- Beta
- —
- Avg daily volume
- $77.0M
- 20-session drawdown
- -6.1%
- 60-session drawdown
- -34.0%
- Latest volume / prior median
- 1.0×
VALUATION
- Market cap
- —
- P/E
- —
FUNDAMENTALS
- Revenue
- $0.0
- Net income
- $-378.0M
- Operating profit
- $-384.6M
- Equity
- $245.5M
- Cash
- $327.3M
- Debt
- $196.2M
- Operating cash flow
- $-300.0M
- Free cash flow
- $-300.6M
- Profit margin
- —
- ROE
- —
- Industry
- —
Prices to 05 Nov 2026: price cache (yfinance). From OpenBB/yfinance, captured 29 Oct 2026: Revenue, Net income, Equity, Operating profit, Cash, Debt, Operating cash flow, Free cash flow. It does not affect the insider score or rank.
Dividends
No cash dividend in the last five years.
Yahoo Finance: cash dividends by ex-dividend date, the latest close, the payout ratio (dividends ÷ 12-month earnings per share) and announced dates; special dividends included, stock dividends and splits not. Not part of any score.
Insiders and institutions
Insiders, ranking window: $11.1M net bought · buyers: 1 · last 2026-10-26
Holders of more than 5% (SEC Schedules 13D and 13G)
| Holder | Of the class | Schedule | As of | Change |
|---|---|---|---|---|
| FMR LLC · large asset manager | 15.00% | 13G | 2024-12-31 · over a year ago | — |
| Invus Public Equities, L.P. | 8.00% | 13G | 2026-06-30 | −3.40 pp |
| Srinivas Akkaraju | 7.20% | 13D | 2025-10-03 · over a year ago | — |
| Wellington Management Group LLP | 5.60% | 13G | 2025-12-31 | — |
| T. Rowe Price Associates, Inc. · large asset manager | 5.40% | 13G | 2026-03-31 | −1.80 pp |
Filings in the last 12 months
1 new · 0 raised · 3 cut · 2 fell to 5% or less
| As of | Holder | Schedule | Stake | What happened |
|---|---|---|---|---|
| 2026-06-30 | Redmile Group, LLC | 13G | 7.60% → 3.60% | 5% or less |
| 2026-06-30 | Invus Public Equities, L.P. | 13G | 11.40% → 8.00% | cut |
| 2026-03-31 | T. Rowe Price Associates, Inc. | 13G | 7.20% → 5.40% | cut |
| 2026-03-31 | Redmile Group, LLC | 13G | 9.90% → 7.60% | cut |
| 2026-03-13 | The Vanguard Group | 13G | — → 0.00% | 5% or less |
| 2025-12-31 | Wellington Management Group LLP | 13G | — → 5.60% | new holding |
Source: SEC, Schedules 13D and 13G, filed in a structured format since 18 December 2024; earlier filings are not read, so a holder that has not filed since then is not shown. 13D: the holder may seek to influence the company (activists, founders, strategic holders); it must amend within two business days of a change of 1% or more. 13G: the holder states it holds passively; it amends within 45 days after the quarter in which its holding changed materially, so a figure can be months old. The percentage is the filer's own, of the class of shares it names. Context only; not part of the score.
Institutional managers (SEC Form 13F)
- Held on 2026-06-30
- $7.2bn306 managers · 138.7M shares
- Shares held, change on the quarter
- +3.6%since 2026-03-31
- Change on the year
- +26.4%since 2025-06-30
- Managers
- 58 new · 129 added · 83 cut · 26 sold out
The shares 13F managers held changed little on the quarter.
Source: SEC Form 13F, filed within 45 days of each quarter end by managers with $100 million or more in US-listed shares; long positions only (no short positions, options left out). Late filers of the quarter are not counted. A parent and a subsidiary can both report the same shares, so the total can count some twice. The quarter end (2026-06-30) and the insiders' purchases (last 2026-10-26) are different periods. Context only; not part of the score.
Regulatory filings
- Insider filing announcement · published 2026-10-27 · trade date 2026-10-26
- Insider filing announcement · published 2026-09-25 · trade date 2026-09-24
- Insider filing announcement · published 2026-09-23 · trade date 2026-09-21
Unfold all 47 filings
- Insider filing announcement · published 2026-10-27 · trade date 2026-10-26
- Insider filing announcement · published 2026-09-25 · trade date 2026-09-24
- Insider filing announcement · published 2026-09-23 · trade date 2026-09-21
- Insider filing announcement · published 2026-07-06 · trade date 2026-07-01
- Insider filing announcement · published 2026-07-06 · trade date 2026-07-01
- Insider filing announcement · published 2026-07-06 · trade date 2026-07-01
- Insider filing announcement · published 2026-07-06 · trade date 2026-07-01
- Insider filing announcement · published 2026-07-06 · trade date 2026-07-01
- Insider filing announcement · published 2026-06-08 · trade date 2026-06-04
- Insider filing announcement · published 2026-06-08 · trade date 2026-06-04
- Insider filing announcement · published 2026-06-08 · trade date 2026-06-04
- Insider filing announcement · published 2026-06-08 · trade date 2026-06-04
- Insider filing announcement · published 2026-06-08 · trade date 2026-06-04
- Insider filing announcement · published 2026-06-08 · trade date 2026-06-04
- Insider filing announcement · published 2026-06-08 · trade date 2026-06-04
- Insider filing announcement · published 2026-04-24 · trade date 2026-04-23
- Insider filing announcement · published 2026-04-20 · trade date 2026-04-16
- Insider filing announcement · published 2026-04-20 · trade date 2026-04-16
- Insider filing announcement · published 2026-04-20 · trade date 2026-04-16
- Insider filing announcement · published 2026-04-20 · trade date 2026-04-16
- Insider filing announcement · published 2026-02-25 · trade date 2026-02-23
- Insider filing announcement · published 2026-02-19 · trade date 2026-02-17
- Insider filing announcement · published 2026-02-19 · trade date 2026-02-17
- Insider filing announcement · published 2026-02-19 · trade date 2026-02-17
- Insider filing announcement · published 2026-02-19 · trade date 2026-02-17
- Insider filing announcement · published 2026-02-11 · trade date 2026-02-09
- Insider filing announcement · published 2026-02-11 · trade date 2026-02-09
- Insider filing announcement · published 2026-02-11 · trade date 2026-02-09
- Insider filing announcement · published 2026-02-11 · trade date 2026-02-09
- Insider filing announcement · published 2026-02-11 · trade date 2026-02-09
- Insider filing announcement · published 2026-02-11 · trade date 2026-02-09
- Insider filing announcement · published 2026-02-11 · trade date 2026-02-09
- Insider filing announcement · published 2026-02-11 · trade date 2026-02-09
- Insider filing announcement · published 2026-02-06 · trade date 2025-12-11
- Insider filing announcement · published 2026-01-23 · trade date 2026-01-22
- Insider filing announcement · published 2026-01-21 · trade date 2026-01-16
- Insider filing announcement · published 2026-01-21 · trade date 2026-01-16
- Insider filing announcement · published 2026-01-21 · trade date 2026-01-16
- Insider filing announcement · published 2026-01-21 · trade date 2026-01-16
- Insider filing announcement · published 2026-01-16 · trade date 2026-01-14
- Insider filing announcement · published 2026-01-15 · trade date 2026-01-13
- Insider filing announcement · published 2026-01-15 · trade date 2026-01-13
- Insider filing announcement · published 2026-01-15 · trade date 2026-01-13
- Insider filing announcement · published 2026-01-15 · trade date 2026-01-13
- Insider filing announcement · published 2025-12-18 · trade date 2025-12-16
- Insider filing announcement · published 2025-12-16 · trade date 2025-12-12
- Insider filing announcement · published 2025-12-05 · trade date 2025-12-04
Results and insider purchases
| Results (8-K) | Bought within 5 sessions | Bought within 20 sessions | Buyers, 20 sessions before |
|---|---|---|---|
| 2026-08-0607:10 ET · before the open | None | None | 0 |
| 2026-05-0707:10 ET · before the open | None | None | 0 |
| 2026-03-0307:14 ET · before the open | None | None | 0 |
| 2026-01-1209:23 ET · before the open | None | None | 0 |
Results dates are the company's 8-K filings to the SEC under Item 2.02 (results of operations); one filed after the close counts from the next session. Purchases are open-market buys reported on Form 4 (code P), by trade date; a Form 4 can arrive two business days after the trade, so the latest days can still fill in. Facts only; this does not change the score or rank.
Ownership and trading-plan context
| Direct / indirect ownership | Mixed direct / indirect |
|---|---|
| 10b5-1 filing evidence | Not declared in filing field |
| Evidence retrieved | 2026-10-28T23:57:43+00:00 |
These are accession-level filing fields. Unavailable means the evidence was not fetched or parsed; it is never inferred as “No” and does not adjust the US score.
Filing evidence
These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.
Excluded transactions & classification
1 qualifying purchase disclosure(s) · 6 transaction line(s)
Trade Oct 26, 2026Open market purchase
AKKARAJU SRINIVAS · Director
Published Oct 27, 2026 · Common Stock · 48988 shares × 41.59 USD · 2037410.9200000002 USD
Open filingTrade Oct 26, 2026Open market purchase
AKKARAJU SRINIVAS · Director
Published Oct 27, 2026 · Common Stock · 97982 shares × 41.59 USD · 4075071.3800000004 USD
Open filingTrade Oct 23, 2026Open market purchase
AKKARAJU SRINIVAS · Director
Published Oct 27, 2026 · Common Stock · 47000 shares × 41.31 USD · 1941570.0 USD
Open filingUnfold all 3 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Reported value (local currency) | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-23 | 2026-10-27 | AKKARAJU SRINIVAS | Director | Open market purchase | Common Stock | 41.31 USD | USD | 94000 | 3883140.0 USD | Open filing |
| 2026-10-23 | 2026-10-27 | AKKARAJU SRINIVAS | Director | Open market purchase | Common Stock | 41.82 USD | USD | 500 | 20910.0 USD | Open filing |
| 2026-10-23 | 2026-10-27 | AKKARAJU SRINIVAS | Director | Open market purchase | Common Stock | 41.82 USD | USD | 1000 | 41820.0 USD | Open filing |
Showing 6 of 6 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level $ aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Other disclosed transactions · excluded from score
View 73 other transaction(s)
Trade Dec 16, 2025Open market sale
Peng Katie · Director
Published Dec 18, 2025 · Common Stock · 726.0 shares × 43.88 USD · 31856.88 USD
Open filingTrade Dec 16, 2025Open market sale
Peng Katie · Director
Published Dec 18, 2025 · Common Stock · 280.0 shares × 44.63 USD · 12496.400000000001 USD
Open filingTrade Dec 12, 2025In-the-money option exercise
AKKARAJU SRINIVAS · Director
Published Dec 16, 2025 · Common Stock · 1064804.0 shares × 7.35 USD · 7826309.399999999 USD
Open filingUnfold all 70 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Reported value (local currency) | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-04 | 2025-12-05 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise of derivative security | Common Stock | 18.08 USD | USD | 21093.0 | 381361.43999999994 USD | Open filing |
| 2025-12-04 | 2025-12-05 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise of derivative security | Common Stock | 4.86 USD | USD | 5607.0 | 27250.02 USD | Open filing |
| 2025-12-04 | 2025-12-05 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise of derivative security | Common Stock | 7.62 USD | USD | 1281.0 | 9761.22 USD | Open filing |
| 2025-12-04 | 2025-12-05 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise of derivative security | Common Stock | 10.0 USD | USD | 11250.0 | 112500.0 USD | Open filing |
| 2025-12-04 | 2025-12-05 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise of derivative security | Common Stock | 35.15 USD | USD | 8035.0 | 282430.25 USD | Open filing |
| 2025-12-04 | 2025-12-05 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Open market sale | Common Stock | 45.21 USD | USD | 136462.0 | 6169447.0200000005 USD | Open filing |
| 2025-12-04 | 2025-12-05 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise of derivative security | Common Stock | 26.05 USD | USD | 65625.0 | 1709531.25 USD | Open filing |
| 2025-12-04 | 2025-12-05 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise of derivative security | Common Stock | 15.75 USD | USD | 23571.0 | 371243.25 USD | Open filing |
| 2026-02-23 | 2026-02-25 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Open market sale | Common Stock | 46.94 USD | USD | 7427.0 | 348623.38 USD | Open filing |
| 2026-02-23 | 2026-02-25 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Open market sale | Common Stock | 48.48 USD | USD | 200.0 | 9696.0 USD | Open filing |
| 2026-02-23 | 2026-02-25 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Open market sale | Common Stock | 47.86 USD | USD | 857.0 | 41016.02 USD | Open filing |
| 2026-02-17 | 2026-02-19 | Marantz Jing L. | CHIEF MEDICAL OFFICER | Open market sale | Common Stock | 46.53 USD | USD | 4157.0 | 193425.21 USD | Open filing |
| 2026-02-17 | 2026-02-19 | Ho Junlin | GENERAL COUNSEL | Open market sale | Common Stock | 46.53 USD | USD | 9580.0 | 445757.4 USD | Open filing |
| 2026-02-17 | 2026-02-19 | Parlavecchio Caryn | CHRO | Open market sale | Common Stock | 46.53 USD | USD | 9035.0 | 420398.55 USD | Open filing |
| 2026-02-17 | 2026-02-19 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Open market sale | Common Stock | 46.53 USD | USD | 7989.0 | 371728.17 USD | Open filing |
| 2026-02-09 | 2026-02-11 | Vaishnaw Akshay | President of R&D | Grant or award | Common Stock | 0.0 USD | USD | 47021.0 | 0.0 USD | Open filing |
| 2026-02-09 | 2026-02-11 | Sinha Vikas | Chief Financial Officer | Grant or award | Common Stock | 0.0 USD | USD | 47021.0 | 0.0 USD | Open filing |
| 2026-02-09 | 2026-02-11 | Qatanani Mo | Chief Scientific Officer | Grant or award | Common Stock | 0.0 USD | USD | 29258.0 | 0.0 USD | Open filing |
| 2026-02-09 | 2026-02-11 | Parlavecchio Caryn | Chief Human Resources Officer | Grant or award | Common Stock | 0.0 USD | USD | 29258.0 | 0.0 USD | Open filing |
| 2026-02-09 | 2026-02-11 | Marantz Jing L. | Chief Medical Officer | Grant or award | Common Stock | 0.0 USD | USD | 34482.0 | 0.0 USD | Open filing |
| 2026-02-09 | 2026-02-11 | Ho Junlin | General Counsel | Grant or award | Common Stock | 0.0 USD | USD | 36572.0 | 0.0 USD | Open filing |
| 2026-02-09 | 2026-02-11 | Hallal David | Chief Executive Officer | Grant or award | Common Stock | 0.0 USD | USD | 128004.0 | 0.0 USD | Open filing |
| 2026-02-09 | 2026-02-11 | Woods Keith | Chief Operating Officer | Grant or award | Common Stock | 0.0 USD | USD | 47021.0 | 0.0 USD | Open filing |
| 2026-01-22 | 2026-01-23 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Open market sale | Common Stock | 45.87 USD | USD | 2119.0 | 97198.53 USD | Open filing |
| 2026-01-22 | 2026-01-23 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Open market sale | Common Stock | 46.85 USD | USD | 12779.0 | 598696.15 USD | Open filing |
| 2026-01-16 | 2026-01-21 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Open market sale | Common Stock | 44.48 USD | USD | 8406.0 | 373898.87999999995 USD | Open filing |
| 2026-01-16 | 2026-01-21 | Parlavecchio Caryn | CHRO | Open market sale | Common Stock | 44.48 USD | USD | 6600.0 | 293568.0 USD | Open filing |
| 2026-01-16 | 2026-01-21 | Marantz Jing L. | CHIEF MEDICAL OFFICER | Open market sale | Common Stock | 44.48 USD | USD | 5798.0 | 257895.03999999998 USD | Open filing |
| 2026-01-16 | 2026-01-21 | Ho Junlin | GENERAL COUNSEL | Open market sale | Common Stock | 44.48 USD | USD | 8016.0 | 356551.68 USD | Open filing |
| 2026-01-14 | 2026-01-16 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Open market sale | Common Stock | 45.2 USD | USD | 13112.0 | 592662.4 USD | Open filing |
| 2026-01-14 | 2026-01-16 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise of derivative security | Common Stock | 35.15 USD | USD | 2678.0 | 94131.7 USD | Open filing |
| 2026-01-14 | 2026-01-16 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise of derivative security | Common Stock | 18.08 USD | USD | 1407.0 | 25438.559999999998 USD | Open filing |
| 2026-01-14 | 2026-01-16 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise of derivative security | Common Stock | 15.75 USD | USD | 5893.0 | 92814.75 USD | Open filing |
| 2026-01-14 | 2026-01-16 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise of derivative security | Common Stock | 10.0 USD | USD | 2813.0 | 28130.0 USD | Open filing |
| 2026-01-14 | 2026-01-16 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Exercise of derivative security | Common Stock | 7.62 USD | USD | 321.0 | 2446.02 USD | Open filing |
| 2026-01-13 | 2026-01-15 | Sinha Vikas | Chief Financial Officer | Open market sale | Common Stock | 42.7 USD | USD | 16755.0 | 715438.5 USD | Open filing |
| 2026-01-13 | 2026-01-15 | Woods Keith | Chief Operating Officer | Open market sale | Common Stock | 42.7 USD | USD | 16746.0 | 715054.2000000001 USD | Open filing |
| 2026-01-13 | 2026-01-15 | Vaishnaw Akshay | President of R&D | Open market sale | Common Stock | 42.7 USD | USD | 20438.0 | 872702.6000000001 USD | Open filing |
| 2026-01-13 | 2026-01-15 | Hallal David | Chief Executive Officer | Open market sale | Common Stock | 42.7 USD | USD | 57450.0 | 2453115.0 USD | Open filing |
| 2025-12-11 | 2026-02-06 | DEBBANE RAYMOND; Invus Global Management, LLC; Siren, L.L.C. | TenPercentOwner | In-the-money option exercise | Common Stock | 7.35 USD | USD | 1575008.0 | 11576308.799999999 USD | Open filing |
| 2026-06-04 | 2026-06-08 | FLIER JEFFREY S. | Director | Grant or award | Common Stock | 0.0 USD | USD | 6839.0 | 0.0 USD | Open filing |
| 2026-06-04 | 2026-06-08 | Reed Joshua | Director | Grant or award | Common Stock | 0.0 USD | USD | 6839.0 | 0.0 USD | Open filing |
| 2026-06-04 | 2026-06-08 | Brudnick Richard | Director | Grant or award | Common Stock | 0.0 USD | USD | 6839.0 | 0.0 USD | Open filing |
| 2026-06-04 | 2026-06-08 | Burow Kristina | Director | Grant or award | Common Stock | 0.0 USD | USD | 6839.0 | 0.0 USD | Open filing |
| 2026-06-04 | 2026-06-08 | Gilman Michael | Director | Grant or award | Common Stock | 0.0 USD | USD | 6839.0 | 0.0 USD | Open filing |
| 2026-06-04 | 2026-06-08 | Peng Katie | Director | Grant or award | Common Stock | 0.0 USD | USD | 6839.0 | 0.0 USD | Open filing |
| 2026-06-04 | 2026-06-08 | AKKARAJU SRINIVAS | Director | Grant or award | Common Stock | 0.0 USD | USD | 6839.0 | 0.0 USD | Open filing |
| 2026-04-23 | 2026-04-24 | Burow Kristina | Director | Exercise of derivative security | Common Stock | 8.36 USD | USD | 18000.0 | 150480.0 USD | Open filing |
| 2026-04-23 | 2026-04-24 | Burow Kristina | Director | Exercise of derivative security | Common Stock | 9.11 USD | USD | 36000.0 | 327960.0 USD | Open filing |
| 2026-04-23 | 2026-04-24 | Burow Kristina | Director | Exercise of derivative security | Common Stock | 26.78 USD | USD | 7800.0 | 208884.0 USD | Open filing |
| 2026-04-23 | 2026-04-24 | Burow Kristina | Director | Exercise of derivative security | Common Stock | 4.75 USD | USD | 28000.0 | 133000.0 USD | Open filing |
| 2026-04-16 | 2026-04-20 | Woods Keith | Chief Operating Officer | Open market sale | Common Stock | 49.57 USD | USD | 10220.0 | 506605.4 USD | Open filing |
| 2026-04-16 | 2026-04-20 | Vaishnaw Akshay | President of R&D | Open market sale | Common Stock | 49.57 USD | USD | 12246.0 | 607034.22 USD | Open filing |
| 2026-04-16 | 2026-04-20 | Sinha Vikas | Chief Financial Officer | Open market sale | Common Stock | 49.57 USD | USD | 10410.0 | 516023.7 USD | Open filing |
| 2026-04-16 | 2026-04-20 | Hallal David | Chief Executive Officer | Open market sale | Common Stock | 49.57 USD | USD | 30615.0 | 1517585.55 USD | Open filing |
| 2026-09-24 | 2026-09-25 | Woods Keith | Chief Operating Officer | Bona fide gift | Common Stock | 0.0 USD | USD | 48034.0 | 0.0 USD | Open filing |
| 2026-09-21 | 2026-09-23 | Hallal David | Chief Executive Officer | Bona fide gift | Common Stock | 0.0 USD | USD | 36652.0 | 0.0 USD | Open filing |
| 2026-07-01 | 2026-07-06 | FLIER JEFFREY S. | Director | Open market sale | Common Stock | 53.53 USD | USD | 1568.0 | 83935.04000000001 USD | Open filing |
| 2026-07-01 | 2026-07-06 | FLIER JEFFREY S. | Director | Open market sale | Common Stock | 54.88 USD | USD | 15.0 | 823.2 USD | Open filing |
| 2026-07-01 | 2026-07-06 | FLIER JEFFREY S. | Director | Open market sale | Common Stock | 54.24 USD | USD | 1470.0 | 79732.8 USD | Open filing |
| 2026-07-01 | 2026-07-06 | Gilman Michael | Director | Open market sale | Common Stock | 54.81 USD | USD | 43.0 | 2356.83 USD | Open filing |
| 2026-07-01 | 2026-07-06 | Gilman Michael | Director | Open market sale | Common Stock | 53.54 USD | USD | 1346.0 | 72064.84 USD | Open filing |
| 2026-07-01 | 2026-07-06 | Gilman Michael | Director | Open market sale | Common Stock | 54.23 USD | USD | 1155.0 | 62635.649999999994 USD | Open filing |
| 2026-07-01 | 2026-07-06 | Burow Kristina | Director | Open market sale | Common Stock | 53.49 USD | USD | 2105.0 | 112596.45 USD | Open filing |
| 2026-07-01 | 2026-07-06 | Burow Kristina | Director | Open market sale | Common Stock | 54.28 USD | USD | 948.0 | 51457.44 USD | Open filing |
| 2026-07-01 | 2026-07-06 | Reed Joshua | Director | Open market sale | Common Stock | 54.28 USD | USD | 948.0 | 51457.44 USD | Open filing |
| 2026-07-01 | 2026-07-06 | Reed Joshua | Director | Open market sale | Common Stock | 53.5 USD | USD | 2105.0 | 112617.5 USD | Open filing |
| 2026-07-01 | 2026-07-06 | Peng Katie | Director | Open market sale | Common Stock | 53.56 USD | USD | 2988.0 | 160037.28 USD | Open filing |
| 2026-07-01 | 2026-07-06 | Peng Katie | Director | Open market sale | Common Stock | 54.96 USD | USD | 21.0 | 1154.16 USD | Open filing |
| 2026-07-01 | 2026-07-06 | Peng Katie | Director | Open market sale | Common Stock | 54.25 USD | USD | 2437.0 | 132207.25 USD | Open filing |
Showing 73 of 73 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level $ aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Follow new disclosures
Subscribe to new United States disclosures. These are market-wide RSS feeds, not company-specific alerts.
Model & Sources
Signal history
67.8 / 100
Latest recorded score
↓ -1.2 ptssince the first recorded snapshot on 2026-10-28; 8 calendar days observed
- Recorded snapshots
- 5
- First snapshot
- 2026-10-28
There is not yet a 30-calendar-day comparison; earlier scores are not reconstructed. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.
Why did it change?
Less than 30 days of comparable history is available, so factor movement is not yet decomposed.
Signal score history
Fixed 0–100 scale; dates are spaced by calendar time.
Recent recorded points
- 69.0
- 68.9
- 68.2
- 68.0
- 67.8
View all recorded scores
| Snapshot date | Signal score |
|---|---|
| 2026-10-28 | 69.0 |
| 2026-10-29 | 68.9 |
| 2026-11-03 | 68.2 |
| 2026-11-04 | 68.0 |
| 2026-11-05 | 67.8 |
Why this score? · Model details
Priority = 100 × Σ(fixed weight × 0–1 rule-based input)
| Factor | Weight | This company input | Point contribution |
|---|---|---|---|
| 15-day buyer breadth (count) | 35% | 0.200 | 7.0 |
| Qualified-buy size | 25% | 0.923 | 23.1 |
| Role informativeness (inverted) | 20% | 1.000 | 20.0 |
| Recency | 10% | 0.846 | 8.5 |
| Buy/sell conviction | 10% | 0.923 | 9.2 |
This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.
Snapshot & identity
- Snapshot date
- 2026-11-05
- Ticker
- SRRK
- ISIN
- —
- Sector
- Healthcare
- Industry
- —
Company logos by Parqet
How to read Form 4 transaction codes
| Code | Interpretation | Screen treatment |
|---|---|---|
| P | Open-market / private purchase | Buy evidence when the security is qualifying equity |
| S | Sale | Sell evidence when the security is qualifying equity |
| A | Grant / award | Context only |
| F | Tax-related withholding | Context only |
| M | Option exercise | Context only |
| G | Gift | Context only |
| J / L | Other / non-directional | Context only |
P/S rows for options, warrants, compensation units and debt remain visible for audit but are excluded from equity scores and quotes.